ELVN

Enliven Therapeutics, Inc.

Healthcare · Biotechnology

$155.47 sample

+1.21 (+0.78%) 1D

Market cap

$846.0B

Price as of

2026-10-15

Latest filing

8-K · 2026-10-08

Alerts

8

Price$155.47 +5.34% 3M daily closessample

158.28147.59

2026-07-202026-08-112026-09-022026-09-232026-10-15

purchase / approvalsale / rejectionfiling / neutral

Latest events

Filings, trades, FDA; newest first

Oct 08SECForm 144 filed
Oct 01INSInsider buy: Director
Sep 28SEC8-K filed: material event
Sep 17INSInsider buy: 10% owner
Sep 11SEC10-Q filed
Sep 07INSInsider sell: Director
Aug 27INSInsider buy: EVP, Operations
Aug 24INSInsider buy: 10% owner

Sign up to see the real ELVN record →

Company facts

SEC EDGAR registration

Name: Enliven Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Smart-money score: -16sample, -100 to +100
Reporting currency: USD

Who is positioning in ELVN

sample

Insiders: 17 insider transactions over 90 days, net selling, $452.2M
Congress: 5 members traded over 90 days
Institutions · 13F: 8 funds hold $17.6B
Activists · 13D/G: No 13D/13G activist filings on record

How are the fundamentals trending?

sample, by period end

Revenue$27.5B +20.8% y/y

Q4 2024Q3 2026

Inventory$16.9B +16.2% y/y

Q4 2024Q3 2026

Accounts receivable$12.0B +12.7% y/y

Q4 2024Q3 2026

Total debt$32.0B +8.9% y/y

Q4 2024Q3 2026

Peers

sample

Sample peer A: $364.5B -10.2% 3M
Sample peer B: $493.6B -8.3% 3M
Sample peer C: $371.6B +1.4% 3M
Sample peer D: $404.5B -6.0% 3M
Sample peer E: $488.6B +13.7% 3M